Open Access, Peer-reviewed
pISSN 2288-6575
eISSN 2288-6796
    J Korean Surg Soc. 2009 Jul;77(1):29-36. Korean.
    Published online Jul 03, 2009.
    https://doi.org/10.4174/jkss.2009.77.1.29
    Copyright © 2009 The Korean Surgical Society
    Original Article

    Clinical Significance of p53, Ki-67 and Galectin-3 Expressions in Papillary Thyroid Carcinoma

    Byung Seup Kim, M.D., Kyung Ho Kang, M.D., Young Ah Lim, M.D. and Lee Su Kim, M.D.
      • Division of Breast and Endocrine Surgery, Hallym University Sacred Heart Hospital, College of Medicine, Hallym University, Anyang, Korea.
    • Corresponding author (Email: lskim0503@hallym.ac.kr )
    Received February 27, 2009; Accepted April 07, 2009.

    Abstract

    Purpose

    There are few molecular markers useful in practice for predicting prognosis of papillary thyroid carcinoma (PTC) despite numerous basic researches. The objective of this study was to evaluate the prognostic values of several candidate markers of PTC (p53, Ki-67 and galectin-3) using immunohistochemistry (IHC), one of the most practical methods.

    Methods

    IHC for p53, Ki-67 and galectin-3 were performed on formalin-fixed paraffin-embedded tissues of 160 PTC specimens using monoclonal antibodies. The associations of the expressions of these markers with multiple clinicopathologic prognostic factors were assessed.

    Results

    The overexpresion rates of p53, Ki-67 and galectin-3 were 48.8%, 64.3% and 97.8%, respectively. Overexpression of p53 protein was positively associated with extrathyroidal extension (P<0.001). In addition, p53 immunoreactivity was more prevalent among Ki-67 overexpressed specimens (P<0.001). Ki-67 immunoreactivity was positively correlated with tumor size (P<0.05), which became more distinct when accompanied with p53 overexpression (P<0.01). In contrast, no relationship between galectin-3 immunoreactivity and clinical prognostic factors was found.

    Conclusion

    Our results suggest that overexpression of p53 protein and Ki-67 in papillary thyroid carcinoma is associated with tumor progression and that IHC for these proteins could be useful for predicting prognosis of patients with PTC.

    Keywords
    Papillary thyroid carcinoma; p53; Ki-67; Galectin-3

    Figures

    Fig. 1
    Immunohistochemical staining for p53 (×200). Nuclear overexpression of p53 protein is shown in the papillary carcinoma cells.

    Fig. 2
    Immunohistochemical staining for Ki-67 (×100). Nuclear mmunoreactivity of Ki-67 is observed in less than 5% of tumor cells, so this was classified as 'negative'.

    Fig. 3
    Immunohistochemical staining for galectin-3 (×400). Cytoplasmic immunoreactivity of galectin-3 is observed in the papillary thyroid carcinoma cells.

    Tables

    Table 1
    Details of primary antibodies used

    Table 2
    p53, Ki-67 and galectin-3 immunohistochemical staining in papillary thyroid carcinoma tissues

    Table 3
    Relationship between overexpression of p53 protein and clinicopathologic features of PTC

    Table 4
    Relationship between overexpression of Ki-67 and clinicopathologic features of PTC

    Table 5
    Relationship between expression of galectin-3 and clinicopathologic features of PTC

    Table 6
    Relation between p53 expression and Ki-67 expression

    Table 7
    Difference in extrathyroidal extension rate of PTC according to expression of p53 and Ki-67

    Table 8
    Difference in tumor size of PTC according to expression of p53 and Ki-67

    References

      1. Ministry for Health, Welfare and Family Affairs. Annual Report of cancer incidence (2005) and survival (1993-2005) in Korea. 2008.
      1. Ain KB. Papillary thyroid carcinoma. Etiology, assessment, and therapy. Endocrinol Metab Clin North Am 1995;24:711–760.
      1. Mazzaferri EL, Jhiang SM. Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer. Am J Med 1994;97:418–428.
      1. Levine AJ, Momand J, Finlay CA. The p53 tumour suppressor gene. Nature 1991;351:453–456.
      1. Farid NR. P53 mutations in thyroid carcinoma: tidings from an old foe. J Endocrinol Invest 2001;24:536–545.
      1. Ito T, Seyama T, Mizuno T, Tsuyama N, Hayashi T, Hayashi Y, et al. Unique association of p53 mutations with undifferentiated but not with differentiated carcinomas of the thyroid gland. Cancer Res 1992;52:1369–1371.
      1. Park SS, Huh JR, Lee SS, Kang YK, Heo DS, Kim CW. Correlation between clinical outcome and proliferation index in diffuse large B-cell lymphoma. Korean J Pathol 1999;33:475–482.
      1. Fukumori T, Kanayama HO, Raz A. The role of galectin-3 in cancer drug resistance. Drug Resist Updat 2007;10:101–108.
      1. Yeo CJ. Tumor suppressor genes: a short review. Surgery 1999;125:363–366.
      1. Dobosz T, Lukienczuk T, Sasiadek M, Kuczynska A, Jankowska E, Blin N. Microsatellite instability in thyroid papillary carcinoma and multinodular hyperplasia. Oncology 2000;58:305–310.
      1. Nigro JM, Baker SJ, Preisinger AC, Jessup JM, Hostetter R, Cleary K, et al. Mutations in the p53 gene occur in diverse human tumour types. Nature 1989;342:705–708.
      1. Nasir A, Catalano E, Calafati S, Cantor A, Kaiser HE, Coppola D. Role of p53, CD44V6 and CD57 in differentiating between benign and malignant follicular neoplasms of the thyroid. In Vivo 2004;18:189–195.
      1. Fritsche M, Haessler C, Brandner G. Induction of nuclear accumulation of the tumor-suppressor protein p53 by DNA-damaging agents. Oncogene 1993;8:307–318.
      1. Park YK, Park HR, Chi SG, Ushigome S, Unni KK. Overexpression of p53 and absent genetic mutation in clear cell chondrosarcoma. Int J Oncol 2001;19:353–357.
      1. Matias-Guiu X, Cuatrecasas M, Musulen E, Prat J. p53 expression in anaplastic carcinomas arising from thyroid papillary carcinomas. J Clin Pathol 1994;47:337–339.
      1. Chen BK, Ohtsuki Y, Furihata M, Takeuchi T, Iwata J, Liang SB, et al. Co-overexpression of p53 protein and epidermal growth factor receptor in human papillary thyroid carcinomas correlated with lymph node metastasis, tumor size and clinicopathologic stage. Int J Oncol 1999;15:893–898.
      1. Dobashi Y, Sakamoto A, Sugimura H, Mernyei M, Mori M, Oyama T, et al. Overexpression of p53 as a possible prognostic factor in human thyroid carcinoma. Am J Surg Pathol 1993;17:375–381.
      1. Godballe C, Asschenfeldt P, Jorgensen KE, Bastholt L, Clausen PP, Hansen TP, et al. Prognostic factors in papillary and follicular thyroid carcinomas: p53 expression is a significant indicator of prognosis. Laryngoscope 1998;108:243–249.
      1. Hosal SA, Apel RL, Freeman JL, Azadian A, Rosen IB, LiVolsi VA, et al. Immunohistochemical Localization of p53 in Human Thyroid Neoplasms: Correlation with Biological Behavior. Endocr Pathol 1997;8:21–28.
      1. Holm R, Nesland JM. Retinoblastoma and p53 tumour suppressor gene protein expression in carcinomas of the thyroid gland. J Pathol 1994;172:267–272.
      1. Goldenberg JD, Portugal LG, Wenig BL, Ferrer K, Wu JC, Sabnani J. Well-differentiated thyroid carcinomas: p53 mutation status and microvessel density. Head Neck 1998;20:152–158.
      1. Zedenius J, Larsson C, Wallin G, Backdahl M, Aspenblad U, Hoog A, et al. Alterations of p53 and expression of WAF1/p21 in human thyroid tumors. Thyroid 1996;6:1–9.
      1. Brown DC, Gatter KC. Monoclonal antibody Ki-67: its use in histopathology. Histopathology 1990;17:489–503.
      1. Hoos A, Lewis JJ, Antonescu CR, Dudas ME, Leon L, Woodruff JM, et al. Characterization of molecular abnormalities in human fibroblastic neoplasms: a model for genotype-phenotype association in soft tissue tumors. Cancer Res 2001;61:3171–3175.
      1. Hoos A, Stojadinovic A, Mastorides S, Urist MJ, Polsky D, Di Como CJ, et al. High Ki-67 proliferative index predicts disease specific survival in patients with high-risk soft tissue sarcomas. Cancer 2001;92:869–874.
      1. Molino A, Micciolo R, Turazza M, Bonetti F, Piubello Q, Bonetti A, et al. Ki-67 immunostaining in 322 primary breast cancers: associations with clinical and pathological variables and prognosis. Int J Cancer 1997;74:433–437.
      1. Carr K, Heffess C, Jin L, Lloyd RV. Immunohistochemical analysis of the thyroid carcinoma initializing antibodies to p53 and Ki-67. Appl Immunohistochem 1993;1:201–207.
      1. Yoshii T, Inohara H, Takenaka Y, Honjo Y, Akahani S, Nomura T, et al. Galectin-3 maintains the transformed phenotype of thyroid papillary carcinoma cells. Int J Oncol 2001;18:787–792.
      1. Kim JH, Han DH, Oh SJ, Rho YS, Ahn HY, Shin HS, et al. Clinical significance of the expression of galectin-3 in thyroid tumor. Korean J Otolaryngol - Head Neck Sur 2006;49:812–816.
    Cited by
    Crossref 5
    Google Scholar 
    MeSH Terms
    Antibodies, Monoclonal
    Carcinoma
    Factor IX
    Galectin 3
    Humans
    Immunohistochemistry
    Prognosis
    Proteins
    Thyroid Gland
    Thyroid Neoplasms
    Metrics
    Share
    Figures
    slide
    slide
    slide

    1 / 3

    Tables
    slide
    slide
    slide
    slide
    slide
    slide
    slide
    slide

    1 / 8

    PERMALINK